# What is ipamorelin? Updated November 2, 2026. Source: https://whatisipamorelin.com/ ## Short answer Ipamorelin is a lab-made peptide of five amino acids that prompts the pituitary gland to release more of the body’s own growth hormone.[1] It is not in any FDA-approved drug, and in 2024 FDA’s compounding advisers voted against adding it to the list of substances pharmacies can use.[1][2] Its main human trial, in bowel surgery patients, found no significant benefit over placebo.[6] ## Latest news: HHS’s draft peptide policy names six peptides. Ipamorelin is not one of them. October 30, 2026. HHS published a notice on October 30, 2026 announcing a **draft** policy on compounding certain peptides.[9] **Ipamorelin and CJC-1295 are not on its list.**[10] The list has six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.[10] For those six, HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound them, as long as every condition in the policy is met.[10] One condition is a single active ingredient, so blends are left out.[10] The policy is not binding on HHS or the public, and comments are due by November 13, 2026 on docket HHS-OASH-2026-0496.[9] TIME described the moment as “The Peptide Rush Has Begun.”[11] Ipamorelin’s record is separate: FDA advisers voted against adding it to the compounding list in 2024.[2] - **Ipamorelin:** Not among the six peptides the policy names.[10] - **CJC-1295:** Also not among the six.[10] - **Blends:** Only products with a single active ingredient from the list qualify.[10] ## Quick fit check If any of these apply, mention them in the assessment: - **You have a pituitary problem:** FDA says ipamorelin would not be expected to raise growth hormone in people with absent pituitaries or severely damaged growth hormone cells.[1] Raise this with the provider. - **You want a treatment FDA has approved:** FDA says there are no FDA-approved drug products containing ipamorelin.[1] FDA-approved treatments do exist for growth hormone deficiency, such as somatropin.[1] - **You have diabetes or high blood sugar:** FDA is concerned that ipamorelin could carry risks like those of approved growth hormone products, including glucose intolerance and diabetes.[1] Raise this with the provider. - **You have or have had cancer:** Approved growth hormone product labels warn of an increased risk of tumors, and FDA is concerned similar risks could apply to ipamorelin.[1] Raise this with the provider. - **You compete in a drug-tested sport:** The World Anti-Doping Agency’s 2026 list names both ipamorelin and CJC-1295 as prohibited.[12] ## Key facts - **What it is:** A synthetic peptide of five amino acids that acts as a ghrelin mimetic and growth hormone secretagogue.[1] - **Not to be confused with:** Pamorelin, a brand of triptorelin.[7] Triptorelin is a GnRH analogue used for conditions such as prostate cancer and early puberty.[8] - **FDA status:** Not in any FDA-approved drug.[1] FDA reviewed it and proposed leaving it off the list of substances that can be used in pharmacy compounding.[1] - **Advisory committee:** In October 2024, FDA’s compounding advisers voted 0 in favor, 12 against, with 1 abstaining, on each form of ipamorelin.[2] - **Best human trial:** A phase 2 trial after bowel surgery found no significant difference from placebo.[6] - **Half-life:** About 2 hours when infused into healthy men, with growth hormone peaking at about 40 minutes.[5] ## Ipamorelin’s record so far | When | What happened | | --- | --- | | 1998 | Researchers described ipamorelin as a selective growth hormone releaser, based on lab, rat and pig studies.[4] | | 1999 | A dose-escalation study in healthy men measured how ipamorelin moves through the body and raises growth hormone.[5] | | 2014 | A phase 2 trial in 114 bowel surgery patients found no significant benefit over placebo.[6] | | September 2023 | FDA placed ipamorelin acetate in category 2, its group of bulk substances that may present significant safety risks, for outsourcing facilities.[3] | | October 2024 | FDA proposed against listing it, and its advisory committee voted 0 to 12, with 1 abstaining.[1][2] | | October 2026 | HHS published a draft policy covering six other peptides.[9][10] | ## How ipamorelin works - **It mimics ghrelin:** Ipamorelin activates ghrelin receptors, mainly in the hypothalamus, which leads the pituitary to release growth hormone.[1] - **It needs a working pituitary:** FDA says ipamorelin would not be expected to raise growth hormone in people with absent pituitaries or severely damaged growth hormone cells.[1] - **It is selective in animals:** In pigs, ipamorelin did not raise the stress hormones ACTH and cortisol beyond what the body’s own releasing hormone did, even at very high doses.[4] FDA also describes it as having no major effect on those hormones.[1] - **It acts in short bursts:** In healthy men given an infusion, it caused a single rise in growth hormone that peaked at about 40 minutes and then fell to negligible levels.[5] ## What the evidence shows - **Recovery after bowel surgery:** In a randomized phase 2 trial, the median time to a first tolerated meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant.[6] The drug was given by IV, and the authors called the study small.[6] - **Growth hormone deficiency:** FDA concluded that evidence of effectiveness is limited for any route, with no data supporting the injected-under-the-skin route proposed for compounding.[1] Professional guidelines do not discuss it for this use.[1] - **Muscle, fat loss, sleep and anti-aging:** Clinics market ipamorelin for uses like these.[1] FDA’s review found no additional data on its effectiveness for other clinical uses.[1] - **With CJC-1295:** Clinics market the two together.[1] A 2026 review reported improved muscle force with the pair in mice with steroid-related muscle loss, and said those findings are limited to animal studies.[14] ## Side effects and safety concerns - **In the bowel surgery trial:** Low potassium (12.5% vs 3.4% on placebo), insomnia (10.7% vs 5.2%) and high blood sugar at discharge (14.3% vs 8.6%) were more common with ipamorelin.[1] Across all side effects combined, rates were 87.5% on ipamorelin and 94.8% on placebo.[6] - **Deaths in that trial:** Two people given ipamorelin died after developing complications from their colon cancer surgery.[1] FDA says it is unclear whether the deaths were related to ipamorelin, but that they raise safety concerns.[1] - **Immune reactions:** FDA is concerned that injected compounded ipamorelin could trigger immune reactions, because of possible clumping and impurities.[1][3] - **Risks tied to growth hormone:** FDA is concerned about risks like those on approved growth hormone labels, including tumors, glucose intolerance and diabetes, raised pressure in the skull, fluid retention and pancreatitis.[1] - **Injected use is largely unstudied:** FDA found no safety or effectiveness data for the under-the-skin route proposed for compounding.[1] It says it lacks enough information to know whether the drug would cause harm by certain other injected routes.[3] - **CJC-1295, the other half of the blend:** FDA has identified serious adverse events with CJC-1295, including increased heart rate and a whole-body blood vessel widening reaction, and calls clinical data limited.[3] Two trials in healthy adults reported no serious adverse reactions.[13] ## Further reading Want each ipamorelin claim graded by its evidence? [PeptideAgent’s ipamorelin profile sorts animal data from human trials](https://peptideagent.ai/peptides/ipamorelin?utm_source=whatisipamorelin&utm_medium=referral&utm_campaign=question-sites) ## Common questions ### Is ipamorelin the same as Pamorelin? No. Ipamorelin is a growth hormone peptide.[1] Pamorelin is an Ipsen brand of triptorelin, a medicine used for conditions such as prostate cancer.[7][8] ### Is ipamorelin FDA-approved? No. FDA says there are no FDA-approved drug products containing ipamorelin.[1] Its compounding advisers voted against adding it to the 503A bulks list in October 2024, with no votes in favor.[2] ### Can pharmacies compound ipamorelin? FDA reviewed it and proposed leaving it off the 503A bulks list, and its advisers agreed.[1][2] FDA’s safety-risk page still lists it as a nominated substance that was withdrawn, and as category 2 for outsourcing facilities.[3] It is also not one of the six peptides in HHS’s draft policy.[10] Ask any provider or pharmacy how their product is sourced. ### Is ipamorelin HGH or a steroid? Neither. It is a five-amino-acid peptide that stimulates the release of the body’s own growth hormone.[1] ### Does ipamorelin build muscle or burn fat? Clinics market it that way, but FDA’s review found no additional effectiveness data beyond growth hormone deficiency and post-surgery bowel recovery, and limited evidence for those.[1] ### Why is ipamorelin paired with CJC-1295? They act on different receptors: ipamorelin on ghrelin receptors, and CJC-1295 as a long-acting analog of growth hormone-releasing hormone.[1][13] A 2026 review said the pair’s muscle findings are limited to animal studies.[14] ### Is ipamorelin banned in sports? Yes. The World Anti-Doping Agency’s 2026 Prohibited List names it among growth hormone secretagogues, and also lists CJC-1295.[12] ## Next step **See if a provider recommends CJC-1295 / ipamorelin.** The option offered here is a blend that contains both CJC-1295 and ipamorelin, not ipamorelin alone. It is compounded and not FDA-approved. Complete an online health assessment, and a licensed provider decides whether it or another option is appropriate for you. What the assessment includes: - Online health assessment - Review by a licensed provider - Shipped to you if prescribed - Card held at checkout, charged only if prescribed How to get started: 1. **Answer health questions.** An online assessment about your health, history and goals. 2. **A licensed provider reviews it.** They decide whether a prescription is safe and appropriate for you. 3. **If prescribed, it ships to you.** Your card is only held at checkout. You’re charged only if a provider prescribes. Not everyone qualifies. A provider decides based on your health history. Start the assessment: https://whatisipamorelin.com/go/md/agent Assessments are completed with a partner telehealth provider. This site may earn a commission if you start one through it. ## Sources 1. FDA Briefing Document, Pharmacy Compounding Advisory Committee: Evaluation of Ipamorelin-related Bulk Drug Substances. U.S. Food and Drug Administration. October 29, 2024 meeting. https://www.fda.gov/media/182088/download 2. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting. U.S. Food and Drug Administration. October 29, 2024. https://www.fda.gov/media/185412/download 3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. Content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks 4. Ipamorelin, the first selective growth hormone secretagogue. Raun K, et al. European Journal of Endocrinology. November 1998. https://pubmed.ncbi.nlm.nih.gov/9849822/ 5. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Gobburu JV, et al. Pharmaceutical Research. September 1999. https://pubmed.ncbi.nlm.nih.gov/10496658/ 6. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Beck DE, et al. International Journal of Colorectal Disease. December 2014. https://pubmed.ncbi.nlm.nih.gov/25331030/ 7. Pamorelin (Triptorelin). Ipsen Germany. April 2026. https://www.ipsen.com/germany/product/pamorelin/ 8. Decapeptyl SR 22.5 mg (triptorelin), patient information leaflet. Ipsen, via the electronic medicines compendium (UK). Accessed November 2, 2026. https://www.medicines.org.uk/emc/files/pil.5906.pdf 9. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526). U.S. Department of Health and Human Services, Federal Register. October 30, 2026. https://www.federalregister.gov/d/2026-22192 10. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B. U.S. Department of Health and Human Services. October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf 11. The Peptide Rush Has Begun. TIME (Alana Semuels). October 28, 2026. https://time.com/article/2026/10/28/peptide-rush-has-begun/ 12. International Standard: Prohibited List 2026. World Anti-Doping Agency. 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf 13. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism. March 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/ 14. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Mayfield CK, et al. American Journal of Sports Medicine. January 2026. https://pubmed.ncbi.nlm.nih.gov/41476424/ --- General education, not medical advice. Talk to a licensed clinician before starting or changing any medicine.